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The effect of 8 weeks treatment with oral iodinated activated charcoal (IAC) on lung function
of patients with moderate chronic obstructive pulmonary disease (COPD) was examined in a
double blind randomized placebo controlled parallel group study with 40 patients. In the
IAC group, patients showed a statistically significant improvement of FEV1 baseline by
130 ml compared to placebo, corresponding to 8.2% improvement (p Z 0.031*). Correlation
statistics revealed that the improvement of FEV1 baseline was significantly correlated both
to FEV1 post-bronchodilator (p Z 0.0020**) and FEV1 post-exercise (0.033*) values. This dem-
onstrates that the improved baseline lung function by IAC did not inhibit a further beta2-
adrenoceptor relaxation, and thus that patients did not reach a limit for maximal improvement
of the lung function after IAC treatment. Eight patients in the IAC group developed abnormal
thyroid hormone levels transiently during the treatment. This side effect was not correlated to
improvement of lung function (p Z 0.82). No serious adverse effects directly related to the
treatment were recorded.
In summary, this study demonstrates that iodinated activated charcoal surprisingly and
significantly improved lung function of patients with moderate COPD. The underlying mecha-
nism of action is unclear, but is likely to be different from the drugs used today. The immediate
conclusion is that further studies are now justified in order to determine clinical efficacy of IAC
in COPD and explore possible mechanisms of action.
ª 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).13 27 78.
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Figure 1 Schedule of investigational events. Tests: A: Phys-
ical examination, B: ECG, C: Laboratory tests, D: Exercise test,
E: Spirometry, F: CAT score, G: St. Georges Respiratory Ques-
tionnaire, H: Adverse events interview. V0: Pre-study
screening. Tests; A, B, C, E, F. This is followed by a 2 week
run-in period. V1: End of run-in period. Tests: A, B, C, D, E, F.
After w3 days the patients return for next visit. V2: Start of
study. Tests: A, B, C, D, E, F, G. After 1 week the patients
return. V3: Simplified hospital visit to detect possible side ef-
fects. Tests: A, B, C, F, H. Another 3 weeks later there is a
phone call. V4: Phone call. Test: H. Another 4 weeks later (in
total 8 weeks treatment) there is another visit. V5: End of
treatment visit Tests: A, B, C, D, E, F, G. Laboratory tests. 
Clinical chemistry: Na, K, Ca, albumin, ALP, GT, ASAT, ALAT,
Cystatin C.  Hematology: hemoglobin, leukocytes, trombo-
cytes, neutrophils, eosinophils, basophiles, lymphocytes,
monocytes.  Thyroid hormones: TSH, T3, T4.
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Chronic obstructive pulmonary disease (COPD) is a common
and severe disease affecting hundreds of millions of people.
It is the 4:th most common cause of death in the world
today, according to a recent fact sheet [12]. COPD has
traditionally been attributed to cigarette smoke, although
today an increasing number of non-tobacco smokers
develop this disease. COPD is characterized by increased
cough and mucous production, reduced stamina, breath-
lessness, increased risk of exacerbations and abnormal rate
of lung function decline [3]. Effective treatments of COPD
beyond a limited response to bronchodilators and in-
terventions that reduce worsening of symptoms at exacer-
bations are lacking.
Current treatment development is hampered by lack of
clinically relevant animal models of the disease as well as
by our limited knowledge of truly important pathogenic
pulmonary and extrapulmonary mechanisms. The current
dissatisfying state of the art is reflected by marginal im-
provements accomplished by newly introduced anti-COPD
drugs and by a liberal testing of a variety of interventions
for possible efficacy in this disease. Some of these attempts
have been published. For example [7], studied effects of
inhalation of thermal water containing bromide-iodide salt
but could not observe any effects on lung function after
two weeks of daily inhalations. Traditional iodide drugs
with reputed mucolytic properties have also been used, but
lack of clinically proved efficacy have lead to recommen-
dations that such compounds should not be used as
mucoregulatory drugs in COPD [8]. One of us (SS) had
developed an interest in possible medical use of iodinated
activated charcoal (IAC) to improve lung function in COPD.
This oral composition would have some potentially benefi-
cial metal scavenging properties [6] but exerts no known
effect that would fit into the currently accepted notions of
mechanisms of COPD. However, three patients with stable
COPD symptoms, who by their own initiative had ingested a
few grams of IAC daily for several weeks, reported sub-
jectively that they experienced clear improvements. This
anecdotal background added to the interest in testing, in a
controlled trial, whether IAC could indeed produce any
acceptable clinical effect in COPD.
Methodology
Patients & design
The clinical trial was a double blind randomized placebo
controlled parallel group study with 40 patients (see Fig. 1
for an overview of the study design). Half of the patients
received IAC and the other half received non-iodinated
activated charcoal. Main inclusion criteria consisted of
45e80 year old males and >1 year post-menopausal, or
surgically sterile females who were smokers and ex-
smokers with at least 15 pack years and had COPD ac-
cording to GOLD II. Main exclusion criteria were abnormal
thyroid function, severely reduced kidney function, exac-
erbation or use of per oral steroids within 4 weeks prior to
the study and severe cardio-vascular or other severe dis-
ease. Primary endpoint was exercise endurance time (EET)at a constant workload exercise test performed at 75% of
maximum work capacity (Wmax) by cycle ergometry 6 h post
dose of IAC, measured in the end of the treatment period,
compared to baseline just before the start of the study.
Secondary endpoints were changes in lung function
measured by spirometry in the hospital (FEV1 and FVC),
COPD assessment (CAT) scale, and St George’s respiratory
questionnaire to determine the quality of life.
Test drug and dosing
Patients were randomized to receive either test substance
(IAC) or placebo (non-iodinated activated charcoal). The
IAC formulation consisted of activated charcoal powder
that had been impregnated with 9% I2 to increase the
mercury binding capacity [6]. IAC was taken in the amount
of 3 g daily for 8 weeks (56 days  2 days). Each dose of IAC
came in a 10 ml glass vial. The IAC was taken in the morning
1 h before breakfast, and swallowed with at least one glass
of water. Other drugs were taken at least 2 h after the IAC,
to avoid drug interactions.
Procedure
When preparing for the pre-study screening visit, the pa-
tients were told to terminate most of their COPD treatment
in advance. Patients were only allowed to use inhaled
corticosteroids at a stable dose, short acting beta2-agonists
and anti-histamines during this trial. The patients who were
included in the study underwent tests during several hos-
pital visits, as described in Fig. 1. During the 2 week run in
period between visit 0 and visit 1, it was examined whether
the lung function was stable in spite of removal of the
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differed more than 10% between visit 0 and visit 1, the
patients were excluded from the study. At visit 1, a
maximum work capacity (Wmax) exercise test was per-
formed. The obtained value was used to determine the
exercise endurance time (EET) during visit 2 (control) and
visit 5 (test value). The EET was performed at a constant
workload at 75% of maximum work capacity (Wmax) by cycle
ergometry 6 h post dose. After undergoing scheduled tests
at visit 2, the patients were randomized to either the
treatment group (20 pat) or the placebo group (20 pat) and
started respective treatment. The treatment with IAC was
implemented over a total of 8 weeks  2 days. The treat-
ment period was concluded by a hospital visit with exami-
nations of all study and safety parameters.
Statistics
Wilcox rank sum test, normal approximation with continuity
correction was used to calculate significance in efficacy
tests. As a measure of correlation, the correlation coeffi-
cient (Pearson’s rho) was computed between FEV1 baseline
and each of the other continuous variables. 95% confidence
intervals and p-values (test of rho Z 0) were determined
using Fisher transformation and normal approximation.
Note: Patient No 131 (IAC group) had a slightly reduced
T4 at the screening visit (11 pmol/L, ref values 12e22), and
Patient 139 (Placebo group) had a slightly elevated TSH at
the screening visit (4 mIE/l, ref values 0.4e3.7). In spite of
this, the patients were admitted into the study. However,
patient 131 was excluded from correlation statistics
regarding iodine effects on the thyroid.
Results
Lung function
Patients in the IAC group showed improved FEV1 after the 8
week treatment period compared to placebo. Baseline
value was increased by 130 ml (8.2%) in average compared
to placebo, post bronchodilator by 140 ml (5.4%) and post
exercise post bronchodilator by 140 ml (7.6%). TheTable 1 Lung function (FEV1 and FVC, absolute and relative ch
IAC Plac
FEV1
Baseline þ70 ml (0.36) 60
4.7% (9.0) 3.
Post- bronchodilator þ100 ml (0.45) 40
5.1% (9.4) 0.
Post-exercise þ110 ml (0.45) 30
6.2% (8.8) 1.
FVC
Baseline þ190 ml (0.70) 50
5.7% (9.9) 0.
Post-bronchodilator þ150 ml (0.86) 10
3.9% (10.1) 1.2%
Post-exercise þ200 ml (0.76) 30
5.7% (8.8) 1.1%improved baseline value was statistically significant
(p Z 0.031*) while post- bronchodilator post-exercise was
close to significance (Table 1).
IAC tended to improve functional vital capacity (FVC)
after the treatment period compared to placebo. Baseline
value was increased by 240 ml (6.1%) in average compared
to placebo, post-bronchodilator by þ160 ml (2.7%) and
post-exercise post-bronchodilator by þ230 ml (4.6%). Both
baseline and post-exercise post-bronchodilator values were
close to significantly improved (Table 1)
Exercise test
The exercise endurance time by cycle ergometry in the IAC
group increased by 11.7% more than in the placebo group
(IAC: 28.0 (62.3), Placebo: 16.7 (82.8)). However, this dif-
ference was not significant (p Z 0.38).
Quality of life questionnaires
The average relative change of the COPD assessment test
(CAT) total score from baseline was 16.1% (sd 26.6) in the
IAC group and 9.5% (sd 28.4) in the placebo group. Thus,
patients in the IAC group had 6% lower CAT symptom scores
than the placebo group, although this change was not sta-
tistically secured (p Z 0.39).
The average relative change from baseline of the total
score of St Georges respiratory questionnaire was 8.2% (sd
26.0) in the IAC group and 2.2% (sd 37.9) in the placebo
group, which was not significant (p Z 0.99).
Sub group analysis
A post hoc analysis was performed in order to identify and
characterize potential high-responding and low-responding
patients (Table 2). There were six patients in the IAC group
that displayed an especially large improvement of the lung
function (FEV1 baseline). This group had an average
improvement of baseline value of þ215 ml, post broncho-
dilator þ248 ml and post exercise þ177 ml. Furthermore,
these six patients also displayed a tendency to a larger
improvement of the total CAT score by 14.9% and anange from baseline, sd).
ebo Total change Significance
ml (0.36) þ130 ml p Z 0.03*
5% (13.7) þ8.2%
ml (0.31) þ140 ml p Z 0.15
3% (11.5) þ5.4%
ml (0.42) þ140 ml p Z 0.067
4% (14.1) þ7.6%
ml (0.53) þ240 ml p Z 0.096
4% (10.5) þ6.1%
ml (0.56) þ160 ml p Z 0.42
(13.7) þ2.7%
ml (0.62) þ230 ml p Z 0.096
(20.4) 4.6%
Table 2 Comparison of different FEV1 tests in six patients
exhibiting the greatest improvement, and six patients
exhibiting the least improvement of FEV1 baseline at the
end of the 8 weeks study in the IAC group, compared to
average placebo values.
Patient
no.
High-sensitivity IAC subgroup
Baseline Post-
bronchodilator
Post-bronchodilator
post-exercise
108 þ360 ml þ410 ml þ170 ml
111 þ150 ml þ200 ml þ140 ml
114 þ370 ml þ490 ml þ480 ml
118 þ130 ml 0 þ40 ml
120 þ170 ml þ250 ml þ90 ml
127 þ110 ml þ140 ml þ140 ml
Average
values
þ215 ml þ248 ml þ177 ml
Patient
no.
Low-sensitivity IAC subgroup
Baseline Post-
bronchodilator
Post-bronchodilator
post-exercise
115 60 ml þ180 ml þ80 ml
126 260 ml 260 ml 100 ml
131 130 ml þ350 ml þ430 ml
133 30 ml þ20 ml 60 ml
136 þ30 ml þ120 ml 0
138 þ30 ml 10 ml 20 ml
Average
values
70 ml þ67 ml þ55 ml
Placebo
Average
values
(n Z 18)
60 ml 40 ml 30 ml
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23.8% (see Table 2).
When compared to six patients in the IAC group with the
least improvement in FEV1 baseline, it seems clear that
there was a considerable difference between patients
regarding the sensitivity to IAC. The low-sensitivity patients
had an average change of baseline value by 70 ml, post
bronchodilator þ67 ml and post exercise þ55 ml. The
reduction by 70 ml of the baseline value was not signifi-
cantly different from the placebo value of 60 ml.
Regarding the background of these patients, four were
males and two females in the high-response group, while
three were males and three females in the low effect
group. The average age was 70.7 years compared to 66.7
years for patients in the high versus low response group,
and the average weight was 75.5 kg compared to 88.7 kg. At
the start of the study, the high sensitivity IAC group had an
average cough and phlegm CAT score of 1.91 and breath-
lessness score of 3.50, while the low sensitivity IAC group
had an average cough and phlegm CAT score of 2.25 and
breathlessness score of 4.17.
Correlation statistics
As a measure of correlation, the relative correlation coef-
ficient was computed between FEV1 baseline and each ofthe other continuous variables. A statistically highly sig-
nificant correlation was found for FEV1 post-bronchodilator
(p Z 0.0020**) and a significant correlation was found for
FEV1 post-exercise (0.0328*). A significant positive corre-
lation between change in FEV1 baseline and FEV1 post-
bronchodilator values indicates that the positive effect by
IAC is present also on top of a bronchodilator, and that
patients do not reach a limit for maximal improvement of
lung function.
The relation between changes in FEV1 baseline and the
occurrence of abnormalities on thyroid hormones was
investigated using logistic regression. The results show no
relationship between changes in FEV1 baseline and occur-
rence of thyroid hormone abnormalities (p Z 0.82).
Safety tolerability
The total number of unique adverse events (AE) was 18 in
the IAC group and 12 in the placebo group. Three patients
discontinued the treatment in the IAC group. This was
caused by severe pharyngo-laryngitis (judged by the
investigator to be unrelated to IAC), COPD exacerbation
and hypothyreosis. Two patients in the placebo group dis-
continued the treatment, both caused by COPD exacerba-
tion. In the IAC group, 8 patients developed abnormal
thyroid values (TSH, T3 or T4) transiently during the
treatment, while none developed this in the placebo group.
Four of the patients with changes in the thyroid function
had only a moderate increase of TSH. Another four patients
also had changes in T4 levels (three had decreased values
and one had increased value). In the subgroup analysis it is
interesting to note that out of the six patients with espe-
cially good effect by IAC, three showed changes of the
thyroid hormone levels, while the other three patients had
normal thyroid values.
Other symptoms in the IAC group included constipation,
diarrhea, joint injury, cough, pruritus and urticaria. In the
placebo group, the patients reported abdominal discom-
fort, constipation, nausea, influenza, nasopharyngitis,
distortion of the sense of taste, parosmia, COPD and
urticaria.
Discussion
The present data suggest that orally administered IAC im-
proves the lung function of patients with moderate COPD.
The number of patients was small (17 in the IAC group and
18 in the placebo group), which means that any effects
would have to be strong to achieve statistical significance.
In spite of this, one test parameter (FEV1 baseline) was
significantly improved by IAC and three additional param-
eters were almost significantly improved. The positive re-
sults are further supported by correlation statistics that
revealed that the improvement of FEV1 baseline was highly
significantly correlated to FEV1 post-bronchodilator and
significantly correlated to FEV1 post-bronchodilator post-
exercise. Hence, although relatively limited in size for this
kind of study (discovery of efficacy of a novel principle in
COPD) the outcome has been positive as regards possible
clinical effect in moderate COPD. This is surprising and
unexpected. It is reasonable to assume that the mechanism
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is distinct from those operating with currently used drugs.
Therefore, it can be argued that the present results may
represent the discovery as well as an early proof of efficacy
of a novel drug principle in COPD.
Due to the evident exploratory nature of this study the
selected primary outcome endpoint had to be arbitrary. We
chose exercise endurance as endpoint. This has been
employed with variable success in previous COPD inter-
vention studies [1]. Although the present mean value in the
cycle endurance test was somewhat greater with IAC than
with placebo this was not statistically significant. It is
possible that our study lacked statistical power for this
test. However, we could demonstrate a significant
improvement in lung function. A significant drug-induced
improvement in lung function without significant effect
on exercise endurance has been reported previously by
[11]. These authors studied effects of a major COPD bron-
chodilator, tiotropium bromide, in patients with similar
severity of COPD disease as in the present study.
The mechanism of action responsible for the present
improvement in lung function is at present unclear. Although
traditionally usedas amucolytic, iodinehas noprovenclinical
efficacy in this regard [8]. Furthermore, steroid-like actions
of IAC are highly unlikely. Similarly, IAC has no known phos-
phodiesterase inhibitory capacity, nor has it any known
interaction with clinically proven bronchorelaxant mecha-
nisms (beta2-adrenoceptor functions or muscarinic receptor
functions). The present findings may prompt further in-
vestigations into the possibility that the mercury-scavenging
property of IAC [5] could somehow bring about beneficial
effects in COPD. One possibility is that mercury contained in
cigarette smoke [10] induces reactive oxygen species such as
H2O2 in the lung and thus causes a range of effects that are
considered pathogenic in COPD. It has previously been shown
that Hg(II) at low concentrations enhances H2O2 formation in
kidneymitochondria [4]. Reactive oxygen species may inhibit
the release of an epithelium-derived relaxing factor from
neuroepithelial endocrine cells in the airway epithelium by
activating a H2O2 sensitive potassium channel, resulting in
constriction of the airways [9]. Clearly, these questions have
to be specifically addressed in future experimental studies
along with other approaches having the dual goal of finding
mechanisms of action of IAC and potentially revealing novel
drug-responsive aspects of COPD. However, drugs known to
inhibit reactive oxygen species have not as yet become suc-
cessful treatments ofCOPD [2]. Similarly, althoughmanyanti-
inflammatory mechanisms are of interest only few have been
established as clinically effective [2]. Hence, the search for
mechanisms behind the present clinical efficacy will have to
be wide and creative, we think.
Half of the patients in the IAC group experienced transient
alterations of the thyroid function. This suggests that some
iodine was released from the IAC in the intestine, absorbed
into the body and interfered with the thyroid function of
these patients. The clinical significance of this adverse effect
has to beevaluated in future studies. Importantly, the thyroid
side effect was not correlated to improvements in FEV1
demonstrating that the improvement in lung functionwas not
causedbychanges in the thyroidhormones. Furthermore, this
also suggests that IAC-responsive patients can be selected
that would not risk developing this side effect.In conclusion, IAC surprisingly improved lung function of
patients with COPD. The mechanism of action is unclear,
but would be quite different from the drugs used today.
The average lung function improvement was moderate
(5e10%), although some patients experienced improved
lung function up to 20%. The immediate conclusion is that
further studies now are justified in order to further deter-
mine clinical efficacy of IAC in COPD and explore possible
mechanisms of action.
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